Clinical trials: Immune System Disease
HIV/AIDS, Psychological Trauma
Efficacy of EMDR Therapy, as Compared to Treatment as Usual, in Reducing Clinical Symptoms in People With HIV
People living with HIV may suffer HIV-related psychological trauma. Studies also show that this group is vulnerable to non-HIV-related trauma. Trauma can increase vulnerability to stress and reducing the ability to cope.
- Conditions
- HIV/AIDS, Psychological Trauma, PTSD
- Trial name
- NCT03848858
- Testing
- EMDR plus TAU
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Parc de Salut Mar
Non Hodgkin Lymphoma, Follicular Lymphoma
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
This is a prospective multicenter phase II pilot trial designed with the purpose of dose finding to evaluate the efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated…
- Trial name
- REAL07 (NCT00907348)
- Testing
- LR-CHOP21
- Where
- 18 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Juvenile Chronic Arthritis
Juvenile Rheumatoid Arthritis
The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.
- Trial name
- NCT00037648
- Testing
- Anakinra
- Volunteers
- 86 people
- Sponsor
- Amgen
Membranous Nephropathy, Nephrotic Syndrome
Belimumab With Rituximab for Primary Membranous Nephropathy
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with…
- Trial name
- REBOOT (NCT03949855)
- Testing
- Belimumab, Rituximab
- Where
- 20 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma
Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture.
- Trial name
- NCT06196255
- Testing
- anti-FcRL5 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuzhou Medical University
Asthma
Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)
This is a randomized, multi-center, parallel-group, active-controlled, double-blind study evaluating the effects of mometasone furoate (MF) dry powder inhaler (DPI) on bone mineral density (BMD) in subjects with asthma.
- Trial name
- NCT00394355
- Testing
- mometasone furoate dry powder inhaler, fluticasone propionate hydrofluoroalkane (HFA), montelukast
- Volunteers
- 566 people
- Sponsor
- Organon and Co
Advanced Solid Tumors or Lymphomas
A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas
This is a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS019 as monotherapy in patients with advanced malignant solid tumors/lymphomas.
- Trial name
- NCT05374226
- Testing
- JS019
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Suzhou Kebo Ruijun Biotechnology Co., Ltd
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Breastmilk Collection, Childhood Obesity
Breastmilk Composition and Microbial Profile in the Growth and Development of Healthy Term-born Infants
An increasing number of children are developing non-communicable diseases that carry immediate and long-term significant societal and economic impacts.
- Conditions
- Breastmilk Collection, Childhood Obesity, Childhood Asthma, Allergy
- Trial name
- NCT06970535
- Where
- 2 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Airway Inflammation, Asthma
An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
This is a randomised, active-comparator, open-label, parallel-group, multicentre phase IV exploratory study to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using SABA…
- Trial name
- NCT03924635
- Testing
- SYMBICORT and salbutamol
- Where
- 6 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Atopic Dermatitis (Eczema)
Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis
Study Overview Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by intense itching and skin barrier damage.
- Trial name
- NCT07573735
- Testing
- blood sampling
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Zhongda Hospital
Systemic Lupus Erythematosus
Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus
Identification of biological markers able to better stratify cardiovascular risks in systemic lupus erythematosus patients is needed.
- Trial name
- TROPOPLUS (NCT04580108)
- Where
- France
- Volunteers
- 446 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetes Mellitus, Diabetes Mellitus, Type 1
Post Approval Study of the Eversense® Continuous Glucose Monitoring
A Post Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System over repeat insertion and removal cycles and to demonstrate the long-term safety of the…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PAS (NCT03908125)
- Testing
- Eversense® CGM System
- Where
- 17 sites in United States
- Volunteers
- 273 people
- Sponsor
- Senseonics, Inc.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
This phase I/II trial studies the side effects and best dose of donor natural killer (NK) cell therapy and to see how well it works when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, donor…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT00789776
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Fred Hutchinson Cancer Center
Pneumococcus; Pneumonia, Hiv
Experimental Pneumococcal Carriage in People Living With HIV
The goal of this experimental pneumococcal carriage study is to to characterise rates and determinants of experimental pneumococcal carriage in PLHIV.
- Trial name
- NCT05698225
- Testing
- Streptococcus pneumoniae serotype 6B
- Where
- Malawi
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Dry Eye Disease
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
- Trial name
- NCT07264517
- Testing
- GRF312 5%
- Where
- 10 sites in United States
- Volunteers
- 103 people
- Sponsor
- Instituto Grifols, S.A.
Lymphomas, B-cell Lymphomas
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
- Trial name
- NCT05773040
- Testing
- JV-213, Leukapheresis
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Lower Limb; Sprain (Strain), Lower Limb Fracture
Implementation of an App-based Walking Aid Skills Training Program
Walking aids (WA), such as crutches, canes, and walkers allow individuals to move independently after lower body impairment. Improper WA use may lead to upper body discomfort, pain, or injury.
- Conditions
- Lower Limb; Sprain (Strain), Lower Limb Fracture, Stroke, Multiple Sclerosis
- Trial name
- NCT05347875
- Testing
- Walking aid skills app, Breathing skills app
- Where
- 2 sites in Canada
- Volunteers
- 52 people
- Sponsor
- University of Calgary
Hereditary Angioedema, Angioneurotic Edema
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Hereditary angioedema ("HAE") is a genetic disorder characterized by sudden recurrent attacks of local swelling (angioedema). These attacks are often painful and disabling, and, in some cases, life-threatening.
- Conditions
- Hereditary Angioedema, Angioneurotic Edema, Genetic Disorders
- Trial name
- NCT00262301
- Testing
- recombinant human C1 inhibitor
- Where
- 2 sites in Netherlands, Romania
- Volunteers
- 75 people
- Sponsor
- Pharming Technologies B.V.
Asthma
Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.
Primary Objective To demonstrate the non-inferiority of Foster® NEXThaler® 100/6 µg versus (vs.) Foster® pressurised metered dose inhaler (pMDI) 100/6 µg in terms of pulmonary function (change from baseline to the entire…
- Trial name
- FORTUNE (NCT03453112)
- Testing
- Foster 100/6µg NEXThaler, Foster 100/6µg pMDI
- Where
- 51 sites in China
- Volunteers
- 494 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.